In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Why Did The European Commission Decide All Antimicrobials Should Be Rx-Only?

Executive Summary

The European Commission responds to questions regarding its decision to include OTC antivirals and antifungals, including commonly used products like thrush and cold sore creams, in the expanded prescription-only requirements for antimicrobials, as part of proposed measures to combat antimicrobial resistance. 

You may also be interested in...

Systemic, Not Topical Antimicrobials Should Be Prescription-Only, Says EU Rapporteur

Topicals should not be included in the proposed prescription-only requirement for antimicrobials, including antifungals and antivirals, suggests EU rapporteur Pernille Weiss in her response to the European Commission's planned overhaul of the EU pharmaceutical legislation. 

AESGP: Rx Status For Antifungals And Antivirals Risks Health System Overload

New prudent use rules that would make some commonly used medicines prescription-only should be restricted to antibiotics, the AESGP tells the European Commission in its feedback to the proposed revision of the region's pharmaceutical legislation. 

German Regulator, Dutch Government Criticize EU’s OTC Antimicrobial Reverse-Switch Plans

The president of the German medicines regulator, BfArM, the Dutch government and industry associations from both countries critisize the proposed EU-wide reverse-switch of OTC antimicrobials, announced at the recent AESGP Annual Meeting.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts